ClinicalTrials.gg
CompletedNCT00786422Updated Nov 18, 2015Results posted

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thrombosis and Deep Vein Thrombosis, sponsored by Bayer. Completed at 16 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-18.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
35th of 36
25 · median 120
Started
2009
the only one that year
Phase 2
4 of 36
none open now
Registered
3rd of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 35th largest by enrollment, is the only one that started in 2009, is one of 4 in phase 2, and was the 3rd registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450 isoenzyme 3A4 (CYP 3A4) inducer for the entire 3-month study duration.

Read the detailed description

The following laboratory variables were determined at baseline at the local laboratories: Hemoglobin, platelets, activated partial thromboplastin time (aPTT), international normalized ratio (INR), alanine aminotransferase (ALT), and creatinine.

03

Conditions studied

  • Venous Thrombosis
  • Deep Vein Thrombosis

Keywords

  • Embolism and Thrombosis
  • Pulmonary Embolism
  • Embolism
  • Venous Thrombosis
  • Thrombosis
  • Enzyme Inducers
  • CYP Inducers
  • Cohort Study
  • Pharmacologic Actions
  • Respiratory Tract Diseases
  • Lung Diseases
  • Vascular Diseases
  • Human Immunodeficiency Virus (HIV)
  • Neurologic disease
  • Additional relevant MeSH terms:
  • Fibrin Modulating Agents
  • Anticoagulants
  • Therapeutic Uses
  • Hematologic Agents
  • Enzyme Inhibitors
  • Cardiovascular Diseases
  • Cardiovascular Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed acute symptomatic proximal deep- vein thrombosis and/or pulmonary embolism
  • Concomitant use of a strong CYP 3A4 inducer, (i.e., carbamazepine, phenytoin, rifampicin/rifampin, and rifabutin)

Exclusion criteria

Exclusion Criteria:

  • Legal lower age limitations (country specific)
  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of deep -vein thrombosis and/or pulmonary embolism
  • Other indication for vitamin K antagonist (VKA) than deep -vein thrombosis and/or pulmonary embolism
  • Concomitant use of strong inhibitors (e.g., protease inhibitors, systemic ketoconazole)
  • Use of the strong CYP 3A4 inducers phenobarbital/primidone or St John's Wort
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939)

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

Interventions

  • Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics - Prothrombin Time (PT), Baseline Value

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Mean and standard deviation (SD) values are presented for PT baseline.

    Time frame: The baseline value of prothrombin time is measured or calculated at a rivaroxaban concentration of 0 µg/L and is based on the observations that were made during the 3 months treatment period

  2. Pharmacodynamics - Prothrombin Time (PT), Slope

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out of PT is in seconds. The PT slope describes the linear increase of PT for one unit increase in concentration, thus the unit of PT slope is s\*(µg/L)\^-1. The final population PK/PD model included a fixed slope that was fitted to the data of the 19 patients that were eligible for evaluation. The estimated mean value (fixed/ the same for all patients in this study) is presented for PT slope.

    Time frame: Up to 3 months treatment

  3. Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban

    AUC(0-24)ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inducer.

    Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

  4. Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban

    Cmax,ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.

    Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

  5. Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban

    Cmin,ss was predicted for each individual participant from rivaroxaban plasma concentrations and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.

    Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

  6. Percentage of Participants With Clinically Relevant Bleeding (i.e. Major Bleeding and Clinically Relevant Non-major Bleeding)

    All events were adjudicated and confirmed by a central independent adjudication committee. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.

    Time frame: Up to 3 months treatment and during subsequent 2 days

Secondary outcomes

  1. Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Non-fatal or Fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

    All events were adjudicated and confirmed by a central independent adjudication committee. The composite efficacy outcome symptomatic recurrent VTE was analyzed descriptively, with the components: Death due to PE, death for which PE cannot be excluded, symptomatic PE and DVT, symptomatic recurrent PE only, and symptomatic recurrent DVT only up to the end of intended treatment period (3 months; 98 study days) and on-treatment (up to 2 days after stop of study drug).

    Time frame: Up to 3 months treatment and during subsequent 30-day observational period for an individual participant

  2. Percentage of Participants With All Deaths

    All deaths were adjudicated by a central independent adjudication committee. Participants who died for any reason were counted for this measure.

    Time frame: Up to 3 months and on-treatment (up to 2 days after stop of study drug) plus an observational period planned for one month

  3. Percentage of Participants With Treatment Emergent Deaths - 7 Days Window

    Treatment emergent deaths were adjudicated by a central independent adjudication committee. Participants who died from treatment emergent adverse events were counted for this measure.

    Time frame: Up to 3 months treatment and during subsequent 7 days

  4. Percentage of Participants With Other Vascular Events

    All events were adjudicated and confirmed by a central independent adjudication committee. Other vascular events comprised ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), unstable angina (UA), ischemic stroke, transient ischemic attack (TIA), non-central nervous system systemic embolism and vascular death.

    Time frame: Up to 3 months treatment and during subsequent 1 day

07

Results

Posted Jun 13, 2014

Participant flow

Participants with confirmed acute proximal symptomatic deep vein thrombosis (DVT) or acute pulmonary embolism (PE) were recruited at specialized study sites.

Rivaroxaban Treatment
Participant flow — Rivaroxaban Treatment
MilestoneRivaroxaban (Xarelto, BAY59-7939)
Started25
Completed14
Not completed11
Withdrew: Death2
Withdrew: Final visit earlier than planned3
Withdrew: Lack of efficacy1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1
Withdrew: Non-compliance with study drug treatment1
Withdrew: Adverse event2
Follow-up Period
Participant flow — Follow-up Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)
Started20
Completed17
Not completed3
Withdrew: Death1
Withdrew: End-of-study done up to 4 days early2

Outcome measures

PrimaryPharmacodynamics - Prothrombin Time (PT), Baseline Value

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Mean and standard deviation (SD) values are presented for PT baseline.

Time frame:
The baseline value of prothrombin time is measured or calculated at a rivaroxaban concentration of 0 µg/L and is based on the observations that were made during the 3 months treatment period
Reported as:
Mean · Seconds
Pharmacodynamics - Prothrombin Time (PT), Baseline Value
SecondsRivaroxaban (Xarelto, BAY59-7939)
Pharmacodynamics - Prothrombin Time (PT), Baseline Value15.8 ± 1.49
PrimaryPharmacodynamics - Prothrombin Time (PT), Slope

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out of PT is in seconds. The PT slope describes the linear increase of PT for one unit increase in concentration, thus the unit of PT slope is s\*(µg/L)\^-1. The final population PK/PD model included a fixed slope that was fitted to the data of the 19 patients that were eligible for evaluation. The estimated mean value (fixed/ the same for all patients in this study) is presented for PT slope.

Time frame:
Up to 3 months treatment
Reported as:
Number · s*(µg/L)^-1
Pharmacodynamics - Prothrombin Time (PT), Slope
s*(µg/L)^-1Rivaroxaban (Xarelto, BAY59-7939)
Pharmacodynamics - Prothrombin Time (PT), Slope0.0389 ± NA
PrimaryPharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban

AUC(0-24)ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inducer.

Time frame:
0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Reported as:
Median · (µg*h)/L
Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban
(µg*h)/LRivaroxaban Initial TreatmentRivaroxaban Extended Treatment
Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban2836 (1259 to 6877)2319 (1059 to 5782)
PrimaryPharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban

Cmax,ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.

Time frame:
0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Reported as:
Median · µg/L
Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban
µg/LRivaroxaban Initial TreatmentRivaroxaban Extended Treatment
Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban200 (150 to 386)167 (126 to 324)
PrimaryPharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban

Cmin,ss was predicted for each individual participant from rivaroxaban plasma concentrations and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.

Time frame:
0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Reported as:
Median · µg/L
Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban
µg/LRivaroxaban Initial TreatmentRivaroxaban Extended Treatment
Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban42 (1 to 170)35 (1 to 143)
PrimaryPercentage of Participants With Clinically Relevant Bleeding (i.e. Major Bleeding and Clinically Relevant Non-major Bleeding)

All events were adjudicated and confirmed by a central independent adjudication committee. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.

Time frame:
Up to 3 months treatment and during subsequent 2 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Relevant Bleeding (i.e. Major Bleeding and Clinically Relevant Non-major Bleeding)
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)
Any confirmed bleeding12.0
Clinically relevant non-major bleeding8.0
Trivial bleeding8.0
SecondaryPercentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Non-fatal or Fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee. The composite efficacy outcome symptomatic recurrent VTE was analyzed descriptively, with the components: Death due to PE, death for which PE cannot be excluded, symptomatic PE and DVT, symptomatic recurrent PE only, and symptomatic recurrent DVT only up to the end of intended treatment period (3 months; 98 study days) and on-treatment (up to 2 days after stop of study drug).

Time frame:
Up to 3 months treatment and during subsequent 30-day observational period for an individual participant
Reported as:
Number · Percentage of participants
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Non-fatal or Fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)
symptomatic recurrent VTE (composite)8.0
Death4.0
Symptomatic recurrent deep vein thrombosis only4.0
SecondaryPercentage of Participants With All Deaths

All deaths were adjudicated by a central independent adjudication committee. Participants who died for any reason were counted for this measure.

Time frame:
Up to 3 months and on-treatment (up to 2 days after stop of study drug) plus an observational period planned for one month
Reported as:
Number · Percentage of participants
Percentage of Participants With All Deaths
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)
Percentage of Participants With All Deaths12.0
SecondaryPercentage of Participants With Treatment Emergent Deaths - 7 Days Window

Treatment emergent deaths were adjudicated by a central independent adjudication committee. Participants who died from treatment emergent adverse events were counted for this measure.

Time frame:
Up to 3 months treatment and during subsequent 7 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Deaths - 7 Days Window
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)
Percentage of Participants With Treatment Emergent Deaths - 7 Days Window8.0
SecondaryPercentage of Participants With Other Vascular Events

All events were adjudicated and confirmed by a central independent adjudication committee. Other vascular events comprised ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), unstable angina (UA), ischemic stroke, transient ischemic attack (TIA), non-central nervous system systemic embolism and vascular death.

Time frame:
Up to 3 months treatment and during subsequent 1 day
Reported as:
Number · Percentage of participants
Percentage of Participants With Other Vascular Events
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)
Percentage of Participants With Other Vascular Events0.0

Adverse events

Collected over For the whole study, adverse event (AE) data were collected during the study course of 25 months. For the individual patient, AE were collected during a treatment period planned for three months plus an observational period planned for one month.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (Xarelto, BAY59-7939)—5/25 (20%)14/25 (56%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban (Xarelto, BAY59-7939)
DeathGeneral disorders2/25
Sudden deathGeneral disorders1/25
HepatitisHepatobiliary disorders1/25
Meningitis cryptococcalInfections and infestations1/25
Vascular dementiaNervous system disorders1/25
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRivaroxaban (Xarelto, BAY59-7939)
Urinary tract infectionInfections and infestations3/25
ArthralgiaMusculoskeletal and connective tissue disorders2/25
NeutropeniaBlood and lymphatic system disorders1/25
TachycardiaCardiac disorders1/25
HaemorrhoidsGastrointestinal disorders1/25
OedemaGeneral disorders1/25
Oedema peripheralGeneral disorders1/25
CellulitisInfections and infestations1/25
HIV test positiveInvestigations1/25
Pain in extremityMusculoskeletal and connective tissue disorders1/25

Baseline characteristics

Age, Customized
Age, Customized(Participants)Rivaroxaban (Xarelto, BAY59-7939)
< 65 years23
65 - 75 years1
> 75 years1
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939)
Female13
Male12
Race
Race(Participants)Rivaroxaban (Xarelto, BAY59-7939)
White1
Black23
Other (mixed South African descent)1
Creatinine clearance
Creatinine clearance(Participants)Rivaroxaban (Xarelto, BAY59-7939)
<30 mL/min0
30 - <50 mL/min0
50 - <80 mL/min4
> 80 mL/min21
Region of recruitment
Region of recruitment(Participants)Rivaroxaban (Xarelto, BAY59-7939)
South Africa - Yes25
South Africa - No0
Participants with history of tuberculosis
Participants with history of tuberculosis(Participants)Rivaroxaban (Xarelto, BAY59-7939)
History of tuberculosis20
No history of tuberculosis5
08

Study locations

16 sites
  • Redcliffe, Queensland 4020, Australia
  • Wien, 1090, Austria
  • São Paulo, Sao Paulo 01323-001, Brazil
  • München, Bayern 80331, Germany
  • Debrecen, 4032, Hungary
  • Ashkelon, 7830604, Israel
  • Holon, 58100, Israel
  • Pavia, 27100, Italy
  • Amsterdam, 1105 AZ, Netherlands
  • Johannesburg, Gauteng 2132, South Africa
  • Johannesburg, Gauteng 2193, South Africa
  • Pretoria, Gauteng 0084, South Africa
  • Pretoria, Gauteng 0157, South Africa
  • Roodepoort, Gauteng 1724, South Africa
  • Somerset West, Western Cape 7130, South Africa
  • Worcester, Western Cape 6850, South Africa
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 1 month after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2008
First posted
Nov 6, 2008
Start
May 2009
Primary completionActual
May 2011
CompletionActual
Jun 2011
Results delay requested
May 15, 2012
Results first posted
Jun 13, 2014
Last update
Nov 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00786422
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 6, 2008
Start date
May 2009
Primary completion
May 2011
Completion
Jun 2011
Results posted
Jun 13, 2014
Last update
Nov 18, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion